FIELD: biotechnology.
SUBSTANCE: invention relates to bispecific binding polypeptide therapeutics specifically targeting cells expressing a specific membrane prostate antigen (SMPA) that can be used in medicine. The resulting polypeptide as well as its dimer and compositions containing them, are used in pharmaceutical compositions for prostate cancer and castration-resistant prostate cancer treatment. The invention allows binding to both SMPA expressing cells and a T-cell receptor complex on T-cells, inducing target-independent T-cell cytotoxicity, activation and proliferation.
EFFECT: increased effectiveness of antitumour therapy.
26 cl, 8 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDES BINDING TO CD3 | 2013 |
|
RU2673153C2 |
| 5T4 AND 4-1BB ANTIGEN-BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | 2018 |
|
RU2804458C2 |
| IMPROVED NOGO-A-BINDING MOLECULES AND PHARMACEUTICAL APPLICATION THEREOF | 2008 |
|
RU2513697C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
| POLYPEPTIDES FOR BONDING WITH "RECEPTOR OF ADVANCED GLYCATION ENDPRODUCTS", THEIR COMPOSITIONS AND METHODS, WHICH THEY TAKE PART IN | 2010 |
|
RU2558301C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| DUAL VARIABLE REGION ANTIBODY-LIKE BINDING PROTEINS HAVING CROSS-OVER BINDING REGION ORIENTATION | 2012 |
|
RU2695880C2 |
| BISPECIFIC ASYMMETRIC HETERODIMERS COMPRISING ANTI-CD3 CONSTRUCTS | 2013 |
|
RU2650868C2 |
